PDGF α receptor is a mediator for Cisplatin-induced Met expression

European Journal of Pharmacology

Volumn 699, Issue 1-3, 2013, Pages 227-232

  Kina, Shinichiro ^a   Phonaphonh, Thongsavanh ^a   Liang, Feixin ^a   Kuang, Hai ^b   Arasaki, Akira ^a   Arakaki, Keiichi ^a   Nakasone, Toshiyuki ^a   Sunakawa, Hajime ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; Met; PDGF receptor

Indexed keywords

CISPLATIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84871987996     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.11.014     Document Type: Article

References (26)

1. M.X. Alexander, and H.H. Paul Receptor tyrosine kinase coactivation networks in cancer Cancer Res. 70 2010 3857 3860
2. S. Angela, Y. Catheryn, D.T. Douglas, and G.T. Cicek Cellular response to chemotherapy and radiation in cervical cancer Am. J. Obstet. Gynecol. 192 5 2005 1399 1403
3. C. Baykal, A. Ayhan, A. Al, K. Yüce, and A. Ayhan Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas Gynecol. Oncol. 88 2 2003 123 129
4. B. Carmen, B. Walter, G. Ermanno, F. George, and W. Vande Met, metastasis, motility and more Nat. Rev. Mol Cell Biol. 4 2003 915 925
5. C.B. Daniel, F. Saijun, and A.W. Kevin Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase and AKT dependent pathways Cancer Res. 60 2000 4277 4283
6. A.H.B. Elizabeth, E.N. Rochelle, R. Vladimir, M.W. Louis, A.G. Erica, and A. Igor Mechanisms of tumor resistance to EGFR targeted therapies Expert Opin. Ther. Targets 13 3 2009 339 362
7. J. Fan, Z. Yun, and J.D. Gregory NADPH Oxidase-Mediated Redox Signaling: Roles in Cellular Stress Response, Stress Tolerance, and Tissue Repair Pharmacol Rev. 63 2011 218 242
8. S. Federica, E.M.O. Ubaldo, and P.L. Michael Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med. 9 2011 62
9. C. Francesco, A. Maria, S. Duhagon, M.H. Elaine, B.T. Suneetha, D. Romano, and L.F. William BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer Int. J. Cancer 128 8 2011 1946 1954
10. Z. Guofei, A.D. Laura, W. Minghua, K. Aileen, T. Humberto, Z. Qiyuan, V. John, and I.S. Jacob Hypoxia-induced alveolar epithelial mesenchymal transition requires mitochondrial reactive oxygen species and hypoxia-inducible factor 1 Am. J. Physiol. Lung. Cell Mol. Physiol. 297 2009 L1120 L1130
11. P. Helene, C. Dennis, and H. Peng Reactive oxygen species stress in cancer cells and therapeutic implications Drug Resist. Update 7 2004 97 110
12. L. Hetian, and K. Andrius Growth factors outside of the platelet derived growth factor (PDGF) family employ reactive oxygen species/src family kinases to activate PDGF receptor α and thereby promote proliferation and survival of cells J. Biol. Chem. 284 10 2009 6329 6336
13. C. Ian, and W. Paul New approaches to molecular cancer therapeutics Nat. Chem. Biol. 2 2006 689 700
14. V. Igor, R. Daniel, V. Matthias, I. Akio, K. Daisuke, O. Barbara, T. Kazuhiro, D. Julie, K. Sara, P. Nicolaos, H. Teli, E. Michael, M. David, W. Daniel, R. Sigrid, R. Ayyappan, M.L. Linda, F.C. Timothy, D. Ivan, B. Cameron, W. Hong, S.M. Paul, P. Timothy, and K.M. Ingo The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation PNAS 107 14 2010 6459 6464
15. M.S. Jayne, C.K. Alec, Y. Haoqiang, N. Roustem, H.P. Aditya, W. Ruprecht, H.Stegh Alexander, E.B. James, L.L. Keith, B. Cameron, C. Lynda, and A.D. Ronald Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 5848 2007 287 290
16. A.E. Jeffrey, Z. Kreshnik, M. Tetsuya, S. Youngchul, H. Courtney, O.P. Joon, L. Neal, M.G. Christopher, Z. Xiaojun, C. James, K. Takayuki, J.H. Alison, M.R. Andrew, C. Federico, M. Tony, L. Charles, E.J. Bruce, C.C. Lewis, and A.J. Pasi MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science 316 5827 2007 1039 1043
17. A. Johanna, G. Radiosa, and B. Christer Role of platelet derived growth factors in physiology and medicine Genes Dev. 22 2008 1276 1312
18. K. Osamu, M. Yoshiji, M. Yoko, O. Miyuki, M. Tamana, Y. Takahiro, W. Kenji, T. Shusaku, K. Tatsuya, S. Iichiro, and S. Yasuhisa Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells Cancer Chemother. Pharmacol. 55 6 2005 584 594
19. S. Peggy, M. Dulabh, T. Xinping, M. Amanda, L. Nick, and P.S.M. Satdarshan Platelet-derived growth factor receptor-A: a novel therapeutic target in human hepatocellular cancer Mol. Cancer Ther. 6 7 2007 1932 1941
20. Z. Peilin, Y.G. Wei, T. Steven, and S.D. Barbara Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro Mol. Cancer 2 2003 1
21. K. Raghu, and Z. Michael Fibroblasts in cancer Nat. Rev. Cancer 6 2006 392 401
22. K. Rajani, N. Vidya, L. Sivakumar, T. Maria, K. Todd, K. Soundararajan, F. Leonardo, C. Philip, N.H. Aliya, E.V. Everett, L. Deborah, and S. Ravi PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription Lab. Invest. 89 2009 301 314
23. T. Stuart, P. Filippo, S.K. Izabela, E. David, and D.H. John Kinase, switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy Clin. Exp. Metastasis 25 8 2008 843 854
24. B. Sylvie, M.A. Daniel, S.S. Laura, S. Deborah, H. Christine, S. Bruno, S. Denise, G. Guenther, L. Congxin, R.H. Anthony, C. Daniel, H.G. Richard, E.L. Kenneth, and Z. Yitzhak The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants Oncogene 23 2004 5387 5393
25. N. Tanaka, A. Miyajima, T. Kosaka, Y. Miyazaki, S. Shirotake, H. Shirakawa, E. Kikuchi, and M. Oya Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer Br. J. Cancer 105 2011 1331 1337
26. W. Yong, and L.S.A. Jessie Role of tumour microenvironment in chemoresistance Cancer Growth Progress. 15 2005 285 321